AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|
20.6 C
New York
Thursday, September 3, 2026

Tag: cases

BrightSpring Health Services, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

LOUISVILLE, Ky., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the second quarter ended June 30, 2025, and increased Revenue and Adjusted EBITDA1 guidance.

ALTAGAS REPORTS STRONG SECOND QUARTER 2025 RESULTS

Robust Performance Across Platform Led by Midstream CALGARY, AB, Aug. 1, 2025 /CNW/ - AltaGas Ltd. ("AltaGas" or the "Company") (TSX: ALA) reported second quarter...

Tenosynovitis Market Research Report 2025-2035 | Rising Demand for Tenosynovitis Treatment Amid Increasing Rheumatoid Arthritis Cases

Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape.
Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape.

Zeekr Group Announces July 2025 Delivery Update

HANGZHOU, China, Aug. 1, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new...

Dr. Shaun Gregory Morgan & Associates Successfully Represented in DIAC Arbitration for $113M Award

New York, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Franklin Morgan & Associates is proud to announce that in a recent ruling, the Dubai International Arbitration Centre (DIAC) has awarded the firm $113 million in a cross-border commercial dispute. The case created a big stir in the legal community not only because of the scope of the dispute, but also for how it positioned Dubai to the world as a high-value destination for international arbitration.

Propel Fuels is Awarded $195 Million Additional Exemplary Damages for Trade Secret Misappropriation by Phillips 66, Bringing Total Award to More Than $833 Million

Kobre & Kim led litigation leading to one of the largest trade secret verdicts in U.S. history. SACRAMENTO, Calif., July 31, 2025 /PRNewswire/ -- California...

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ANRO

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Centene Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CNC

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”), of the important September 8, 2025 lead plaintiff deadline.

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...

Andlauer Healthcare Group Reports 2025 Second Quarter Results

TORONTO, July 31, 2025 /CNW/ - Andlauer Healthcare Group Inc. (TSX: AND) ("AHG" or the "Company") today reported its financial results for the three and...

Fairfax India Holdings Corporation: Second Quarter Financial Results

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

FLINT Announces Second Quarter 2025 Financial Results

Reports Adjusted EBITDAS of $9.6 million, representing a 16% improvement from prior year
Reports Adjusted EBITDAS of $9.6 million, representing a 16% improvement from prior year

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of UY Scuti Acquisition Corp. (NASDAQ: UYSC)

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating UY Scuti Acquisition Corp. (NASDAQ: UYSC) related to its merger with Isdera Group Limited. Upon completion of the proposed transaction, each outstanding UY ordinary share will be converted automatically into a one Class A Ordinary Share of the combined company. Is it a fair deal?

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCases